M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges
N6-methyladenosine (m6A) modification is a pivotal mechanism in RNA epigenetics, with profound implications for lung cancer (LC) biology. This review synthesizes current knowledge on m6A’s multifaceted regulatory networks in non-small cell lung cancer (NSCLC), elucidating its roles in tumor prolifer...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1622359/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849318453239873536 |
|---|---|
| author | Yuyang Yan Jiarui Yin Quan Ding Yan Lu Shuhua Gou Xi Xu Yulin Li |
| author_facet | Yuyang Yan Jiarui Yin Quan Ding Yan Lu Shuhua Gou Xi Xu Yulin Li |
| author_sort | Yuyang Yan |
| collection | DOAJ |
| description | N6-methyladenosine (m6A) modification is a pivotal mechanism in RNA epigenetics, with profound implications for lung cancer (LC) biology. This review synthesizes current knowledge on m6A’s multifaceted regulatory networks in non-small cell lung cancer (NSCLC), elucidating its roles in tumor proliferation, apoptosis, invasion, and metastasis. We further explore how m6A governs metabolic reprogramming—including glycolysis and ferroptosis—angiogenesis, and tumor microenvironment (TME) remodeling. Additionally, m6A-mediated modification of non-coding RNAs contributes to LC malignancy, underscoring its potential as a diagnostic and prognostic biomarker. These findings also offer novel strategies to overcome therapeutic resistance, a critical challenge in NSCLC treatment. Despite its promise, clinical translation of m6A-targeted interventions faces hurdles, such as the lack of standardized detection methods, the complexity of m6A-associated regulatory networks, and unresolved crosstalk with other RNA modifications. Future research should prioritize multi-omics approaches to resolve these challenges and advance m6A from mechanistic discovery toward clinical application. By addressing these gaps, m6A modulation may emerge as a transformative avenue in precision oncology. |
| format | Article |
| id | doaj-art-68bd2bc2caa94cf48a2ac82039296ad3 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-68bd2bc2caa94cf48a2ac82039296ad32025-08-20T03:50:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.16223591622359M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challengesYuyang YanJiarui YinQuan DingYan LuShuhua GouXi XuYulin LiN6-methyladenosine (m6A) modification is a pivotal mechanism in RNA epigenetics, with profound implications for lung cancer (LC) biology. This review synthesizes current knowledge on m6A’s multifaceted regulatory networks in non-small cell lung cancer (NSCLC), elucidating its roles in tumor proliferation, apoptosis, invasion, and metastasis. We further explore how m6A governs metabolic reprogramming—including glycolysis and ferroptosis—angiogenesis, and tumor microenvironment (TME) remodeling. Additionally, m6A-mediated modification of non-coding RNAs contributes to LC malignancy, underscoring its potential as a diagnostic and prognostic biomarker. These findings also offer novel strategies to overcome therapeutic resistance, a critical challenge in NSCLC treatment. Despite its promise, clinical translation of m6A-targeted interventions faces hurdles, such as the lack of standardized detection methods, the complexity of m6A-associated regulatory networks, and unresolved crosstalk with other RNA modifications. Future research should prioritize multi-omics approaches to resolve these challenges and advance m6A from mechanistic discovery toward clinical application. By addressing these gaps, m6A modulation may emerge as a transformative avenue in precision oncology.https://www.frontiersin.org/articles/10.3389/fonc.2025.1622359/fullM6Anon-small cell lung cancertherapeutic strategiesmetabolic reprogrammingRNA epigenetic regulation |
| spellingShingle | Yuyang Yan Jiarui Yin Quan Ding Yan Lu Shuhua Gou Xi Xu Yulin Li M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges Frontiers in Oncology M6A non-small cell lung cancer therapeutic strategies metabolic reprogramming RNA epigenetic regulation |
| title | M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges |
| title_full | M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges |
| title_fullStr | M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges |
| title_full_unstemmed | M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges |
| title_short | M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges |
| title_sort | m6a rna modification focusing on non small cell lung cancer progression therapeutic strategies and challenges |
| topic | M6A non-small cell lung cancer therapeutic strategies metabolic reprogramming RNA epigenetic regulation |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1622359/full |
| work_keys_str_mv | AT yuyangyan m6arnamodificationfocusingonnonsmallcelllungcancerprogressiontherapeuticstrategiesandchallenges AT jiaruiyin m6arnamodificationfocusingonnonsmallcelllungcancerprogressiontherapeuticstrategiesandchallenges AT quanding m6arnamodificationfocusingonnonsmallcelllungcancerprogressiontherapeuticstrategiesandchallenges AT yanlu m6arnamodificationfocusingonnonsmallcelllungcancerprogressiontherapeuticstrategiesandchallenges AT shuhuagou m6arnamodificationfocusingonnonsmallcelllungcancerprogressiontherapeuticstrategiesandchallenges AT xixu m6arnamodificationfocusingonnonsmallcelllungcancerprogressiontherapeuticstrategiesandchallenges AT yulinli m6arnamodificationfocusingonnonsmallcelllungcancerprogressiontherapeuticstrategiesandchallenges |